Guangzhou Cellprotek Pharmaceutical Co., Ltd., founded in April 2011 in the Science Park of Guangzhou, is a comprehensive biopharmaceutical company integrating new drug discovery, technology consulting and technology transfer. Up until now, our R&D team has been powered by many domestic and overseas experts and talents, including over 10 doctoral graduates, while above 60% of our research staff possesses a master degree. Cellprotek has formed a mature business and operation model, and implemented a standardized and systematic management system to back our R & D.
Cellprotek is committed to solving the unmet clinical needs of major acute and chronic neurodegenerative diseases, with innovative small molecule drugs. In addition, the company has launched development of healthcare products for the prevention of these diseases. Currently, there are 5 drug candidates in our R&D pipeline, and we have filed in more than 100 patent applications at home and abroad with over 60 being authorized, covering 48 countries or regions. Our R & D team has published over 20 academic articles, and received multiple honors and supports from different governmental projects, such as the National Science and Technology Major Project, the National Key Overseas Chinese Entrepreneurship Team, the Innovative R & D Organization of Guangdong Province and the Introduced Innovative Entrepreneurship Team of Guangdong Province.
Solve The Unmet Clinical Needs For The Treatment Of CNS Diseases.
Become a pioneer in the discovery of innovative small molecule drugs
Science Honesty Excellence Diligence Teamwork